CD38 dysregulation and gene variation is reported in neurodegenerative conditions such as Parkinson's disease (PD) and Alzheimer's disease (AD), highlighting the need to better understand CD38 biology within the brain. This evidence concerns the gene CD38 and early-onset autosomal dominant Alzheimer disease.